


Carbidopa

Cat. No.:	HY-B0311		
CAS No.:	28860-95-9		
Molecular Formula:	C ₁₀ H ₁₄ N ₂ O ₄		
Molecular Weight:	226.23		
Target:	Aryl Hydrocarbon Receptor		
Pathway:	Immunology/Inflammation		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 10 mg/mL (44.20 mM; Need ultrasonic)
 H₂O : < 0.1 mg/mL (insoluble)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	4.4203 mL	22.1014 mL	44.2028 mL
	5 mM	0.8841 mL	4.4203 mL	8.8406 mL
	10 mM	0.4420 mL	2.2101 mL	4.4203 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 1 mg/mL (4.42 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: ≥ 1 mg/mL (4.42 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 1 mg/mL (4.42 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Carbidopa ((S)-(-)-Carbidopa), a peripheral decarboxylase inhibitor, can be used for the research of Parkinson's disease. Carbidopa is a selective aryl hydrocarbon receptor (AhR) modulator. Carbidopa inhibits pancreatic cancer cell and tumor growth^{[1][2]}.

In Vitro

Carbidopa ((S)-(-)-Carbidopa) exhibits activities similar to that described for other AhR ligands in BxPC3 and Capan-2 cells, namely the induction of CYP1A1 and CYP1A2, which are inhibited by AhR antagonists such as CH223191^[1].

	MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	Carbidopa also induces nuclear uptake of the AhR, and in vivo studies show that carbidopa at a dose of 1 mg/mouse significantly inhibits tumor growth in athymic nude mice bearing B χ PC3 cells as xenografts ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

- [1]. Safe S. Carbidopa: a selective Ah receptor modulator (SAhRM). *Biochem J.* 2017;474(22):3763-3765. Published 2017 Nov 6.
- [2]. Fermaglich J. Treatment of Parkinson's disease with carbidopa, a peripheral decarboxylase inhibitor, and levodopa. *Med Ann Dist Columbia.* 1974;43(12):587-591.
-

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA